Universitätsklinikum Hamburg-Eppendorf
Quick facts
Marketed products
Phase 3 pipeline
- Adjuvant Nivolumab and Ipilimumab · Oncology
Nivolumab and ipilimumab together block immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor T-cell responses in adjuvant settings. - CMF Chemotherapy · Oncology
CMF is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis. - ERVEBO® (rVSV∆G-ZEBOV-GP) · Immunology / Infectious Disease
ERVEBO is a live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Universitätsklinikum Hamburg-Eppendorf portfolio CI brief
- Universitätsklinikum Hamburg-Eppendorf pipeline updates RSS
Frequently asked questions about Universitätsklinikum Hamburg-Eppendorf
What are Universitätsklinikum Hamburg-Eppendorf's marketed drugs?
Top marketed products include Cefuroxime 4,5g.
What is Universitätsklinikum Hamburg-Eppendorf's pipeline?
Universitätsklinikum Hamburg-Eppendorf has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Adjuvant Nivolumab and Ipilimumab, CMF Chemotherapy, ERVEBO® (rVSV∆G-ZEBOV-GP).
Related
- Cefuroxime 4,5g
- Sector hub: All tracked pharma companies